{
    "nctId": "NCT04999540",
    "briefTitle": "Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer",
    "officialTitle": "Trial of Tucidinostat in Combination With Fulvestrant in Patients With Hormone-receptor Positive Advanced Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 73,
    "primaryOutcomeMeasure": "Progression Free Survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients aged 18-75 years (including cutoff value);\n2. The disease condition is inoperable, recurrent breast cancer, or metastatic breast cancer;\n3. Histological or cytological confirmation of hormone receptor-positive \\[estrogen receptor (ER) positive and progesterone receptors (PgR) positive or negative\\] breast cancer;\n4. At least one measurable lesion according to RECIST 1.1;\n5. Prior treatment: have not received systemic chemotherapy for recurrent or metastatic breast cancer;\n6. Eastern Cooperative Oncology Group Performance Status of 0-1;\n7. Adequate function of major organs meets the following requirements):\n\n   Absolute Neutrophils count\u2265 1.5\u00d710\\^9/L; Platelets count\u2265 90\u00d710\\^9/L; Hemoglobin \u2265 90g/L; Total bilirubin\u2264 1.5 \u00d7 the upper limit of normal (ULN); ALT and AST \u2264 2.5 \u00d7 ULN; BUN and Cr \u2264 1.5 \u00d7 ULN; Left ventricular ejection fraction (LVEF) \u2265 50%; QTcF(Fridericia correction) \u2264 470 ms; International normalized ratio(INR)\u22641.5 \u00d7 ULN; activated partial thromboplastin time(APTT) \u2264 1.5 \u00d7 ULN;\n8. Life expectancy \u2265 3 months;\n9. Have signed informed consent.\n\nExclusion Criteria:\n\n1. Patients have untreated central nervous system (CNS) metastases;\n2. Patients with no measurable lesion according to RECIST 1.1;\n3. Patients with bilateral breast cancer;\n4. Patients with human epidermal growth factor receptor-2 (Her-2) positive;\n5. Recurrent or metastatic disease occurs within 2 years during adjuvant endocrine therapy;\n6. Patients previously received systemic chemotherapy for recurrent or metastatic breast cancer;\n7. Patients previously received any HDAC inhibitor or fulvestrant treatment;\n8. There are ascites, pleural effusion, pericardial effusion with clinical symptoms at baseline, those who need drainage, or those who have undergone drainage of serous effusion within 4 weeks before the first dose;\n9. Inability to swallow, intestinal obstruction or other factors affecting the administration and absorption of the drug;\n10. Patients with other invasive malignancies within 5 years or at the same time, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ;\n11. Patients with a history of allergies to the drug components of this regimen;\n12. Patients with active HBV and HCV infection; stable hepatitis B after drug treatment (HBV virus copy number is higher than the upper limit of reference value) and cured hepatitis C patients (HCV virus copy number exceeds the lower limit of detection method) can be included;\n13. Patients with a history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency disease, history of organ transplantation;\n14. Patients have uncontrolled or significant cardiovascular disease, including: Myocardial infarction (\\< the last 12 months); Uncontrolled angina (\\< the last 6 months); Congestive heart failure (\\< the last 6 months), or Left Ventricular Ejection Fraction (LVEF) \\< 50% prior to study entry;\n15. Any mental or cognitive disorder, that would interfere the ability to understand the informed consent document or the operation and compliance of study;\n16. Any other condition which is inappropriate for the study in the opinion of the investigators.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}